Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs...